Aureon Information

Aureon is a life science company founded in 2002, dedicated to enabling the advancement of predictive and personalized cancer treatment options. Aureon employs a unique Systems Pathology approach and provides personalized test results by analyzing a patient’s existing biopsy sample using molecular diagnostics, sophisticated tissue-based image analysis and advanced mathematics. The resulting information is objective, predictive & personalized and allows the patient and his doctor to make more-informed treatment decisions. In addition to our clinical tests, Aureon also collaborates with bio-pharmaceutical partners to apply our innovative platform to drug discovery and clinical development. Although our initial research focus has been on prostate cancer, we have completed pilot projects in other cancer areas and we are interested in working with partners in the areas of non-small cell lung cancer, breast cancer, bladder cancer, and colorectal cancer. Aureon is a founding member of the 21st Century Medicine Coalition & the NY BioHud Valley, a member of the Personalized Medicine Coalition & the American Clinical Laboratory Association. Aureon was co-founded by leading physicians and scientists at Memorial Sloan-Kettering Cancer Center, Yale Cancer Center, and Albert Einstein College of Medicine. Our investors include New Leaf Venture Partners/Sprout Group, BD Ventures, Pfizer Strategic Investments and Atlas Venture. Aureon’s central laboratory is located in Yonkers, New York. Specialties Prognostic Services, Risk Assessment Tools for Prostate Cancer, Partnership and IP Licensing Opportunities, R&D; and Business Development Opportunities